After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. | After Novartis and Roche grew their sales last year, the ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...

The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

FRANKFURT, Jan 31 (Reuters) - The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

The question is: Will the company take it? “We’re certainly watching the space,” Novartis CEO Vas Narasimhan, M.D., said of PD-1xVEGF bispecifics during a fourth-quarter earnings call with ...

Data for December were not yet available. Kisqali is undergoing “a very rapid launch” in early breast cancer, Novartis CEO Vas Narasimhan said during a media call Friday. As Narasimhan shared ...

BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...

Novartis (NVS) CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if its main focus remains on therapeutic areas where it ...

It also saw increased use in China and Japan for hypertension management. In an interview with CNBC, Novartis CEO Vas Narasimhan downplayed concerns about Entresto’s U.S. patent expiration ...